BioLife Solutions Inc (NASDAQ:BLFS) VP James Mathers sold 7,500 shares of BioLife Solutions stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $20.45, for a total transaction of $153,375.00. Following the completion of the sale, the vice president now directly owns 19,884 shares in the company, valued at approximately $406,627.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

James Mathers also recently made the following trade(s):

  • On Tuesday, August 20th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $20.06, for a total transaction of $50,150.00.
  • On Tuesday, August 6th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $17.87, for a total transaction of $44,675.00.
  • On Thursday, August 8th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $18.21, for a total transaction of $45,525.00.
  • On Tuesday, July 23rd, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $18.38, for a total transaction of $45,950.00.
  • On Thursday, July 25th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $19.71, for a total transaction of $49,275.00.
  • On Thursday, July 11th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $17.15, for a total transaction of $42,875.00.
  • On Tuesday, July 9th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $17.94, for a total transaction of $44,850.00.

BioLife Solutions stock traded down $0.04 during mid-day trading on Thursday, reaching $20.74. The company’s stock had a trading volume of 133,200 shares, compared to its average volume of 174,165. BioLife Solutions Inc has a 12-month low of $9.15 and a 12-month high of $26.35. The company has a market capitalization of $383.86 million, a P/E ratio of 148.14 and a beta of 1.37. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.71 and a current ratio of 9.42. The firm’s fifty day moving average price is $18.05 and its two-hundred day moving average price is $17.61.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. BioLife Solutions had a net margin of 14.60% and a return on equity of 8.65%. The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $6.59 million. On average, research analysts predict that BioLife Solutions Inc will post 0.1 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of BioLife Solutions by 32.3% during the second quarter. Price T Rowe Associates Inc. MD now owns 29,626 shares of the medical equipment provider’s stock valued at $502,000 after buying an additional 7,226 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of BioLife Solutions during the second quarter valued at approximately $709,000. Marshall Wace LLP grew its holdings in shares of BioLife Solutions by 39.4% during the second quarter. Marshall Wace LLP now owns 42,200 shares of the medical equipment provider’s stock valued at $715,000 after buying an additional 11,922 shares during the last quarter. Morgan Stanley grew its holdings in shares of BioLife Solutions by 17.5% during the second quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock valued at $195,000 after buying an additional 1,713 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of BioLife Solutions by 4.7% during the second quarter. Invesco Ltd. now owns 81,319 shares of the medical equipment provider’s stock valued at $1,378,000 after buying an additional 3,669 shares during the last quarter. Hedge funds and other institutional investors own 47.86% of the company’s stock.

A number of research analysts recently weighed in on BLFS shares. HC Wainwright started coverage on shares of BioLife Solutions in a research note on Monday, July 22nd. They issued a “buy” rating and a $23.00 price objective for the company. Zacks Investment Research lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. BidaskClub upgraded shares of BioLife Solutions from a “buy” rating to a “strong-buy” rating in a research note on Thursday. ValuEngine lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Finally, Northland Securities reiterated a “buy” rating and issued a $18.00 price objective on shares of BioLife Solutions in a research note on Tuesday, July 9th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. BioLife Solutions currently has an average rating of “Buy” and a consensus target price of $18.67.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Article: Strike Price

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.